Shiota G, Oyama K, Noguchi N, Takano Y, Kitaoka S, Kawasaki H
Second Department of Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Japan.
Res Commun Mol Pathol Pharmacol. 1998 Jul;101(1):3-12.
The Fas ligand (FasL), a member of the tumor necrosis factor family, induces apoptosis in Fas-expressing cells. A matrix metalloproteinase-like enzyme cleaves the membrane-bound FasL to produce the soluble FasL (sFasL). Since FasL has been reported to play a pivotal role in the development of hepatitis, we evaluated clinical significance of serum sFasL in acute liver injury including acute self-limited and fulminant hepatitis. Serum sFasL in 19 patients including 12 with acute self-limited hepatitis and 7 with fulminant hepatitis was measured by an enzyme-linked immunosorbent assay (ELISA). The clinical data consisted of 18 indices including age, sex, liver function tests, hepatocyte growth factor (HGF), outcome and sFasL. Serum sFasL in fulminant hepatitis is 0.06+/-0.01 ng/ml, being identical to that in acute self-limited hepatitis, Serum sFasL is positively correlated with AST and ALT (p<0.0001 and p<0.0001). The factors associated with outcome of the patients were HGF, albumin, prothrombin time, platelet count, cholinesterase and leukocyte count in this order. Serum sFasL serves as an indicator of liver injury in acute self-limited and fulminant hepatitis.
Fas配体（FasL）是肿瘤坏死因子家族的一员，可诱导表达Fas的细胞发生凋亡。一种基质金属蛋白酶样酶可切割膜结合型FasL，产生可溶性FasL（sFasL）。由于据报道FasL在肝炎的发展过程中起关键作用，我们评估了血清sFasL在包括急性自限性肝炎和暴发性肝炎在内的急性肝损伤中的临床意义。通过酶联免疫吸附测定（ELISA）检测了19例患者的血清sFasL，其中包括12例急性自限性肝炎患者和7例暴发性肝炎患者。临床数据包括年龄、性别、肝功能检查、肝细胞生长因子（HGF）、预后和sFasL等18项指标。暴发性肝炎患者的血清sFasL为0.06±0.01 ng/ml，与急性自限性肝炎患者的血清sFasL相同。血清sFasL与谷草转氨酶（AST）和谷丙转氨酶（ALT）呈正相关（p<0.0001和p<0.0001）。与患者预后相关的因素依次为HGF、白蛋白、凝血酶原时间、血小板计数、胆碱酯酶和白细胞计数。血清sFasL可作为急性自限性肝炎和暴发性肝炎肝损伤的一个指标。
